Updated:
Abzena
Abzena is a asset manager based in Cambridge; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...
Abzena
Abzena is a fully integrated biopharmaceutical CDMO+CRO for antibodies, ADCs, AOCs, RDCs, vaccines, from discovery thru commercial.
General information
Firm type
Asset Manager
Location
Region
Europe
Country
United Kingdom
City
Cambridge
Corporate office
Cambridge, United Kingdom
Additional offices
San Diego, CA, USA · Bristol, PA, USA
Sector focus
Frequently asked questions
What services does Abzena offer?
Abzena provides integrated biologics and bioconjugates CDMO+CRO services covering antibody discovery, engineering, developability assessment, analytics, immunogenicity assays, cell line development, formulation, process development, and cGMP manufacturing for clinical through commercial supply.
Where are Abzena's facilities located?
Abzena operates three facilities: San Diego, CA (development and manufacturing), Bristol, PA (discovery and manufacturing), and Cambridge, UK (development and discovery).
What modalities does Abzena work with?
Abzena works with monoclonal antibodies, antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), radiopharmaceutical drug conjugates (RDCs), fusion proteins, bispecifics, and other complex biologics.
Does Abzena have proprietary technologies?
Yes, Abzena has developed several proprietary platforms including AbZelectPRO cell line development, EpiScreen 2.0 immunogenicity testing, Composite Human Antibody humanization, ThioBridge conjugation linker, and LabZient analytical data platform.
Does Abzena only serve large pharma?
No, Abzena serves pharmaceutical and biotech companies of all sizes, with a stated focus on complex and challenging programs that other CDMOs may avoid.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: